investor day takeaway well-posit anoth strong year
adj ep
debt total capit
ew held annual investor day last week meet ew re-affirmed
guidanc provid initi guidanc expect top
bottom-lin pipelin updat somewhat mix view encourag
learn next-gen balloon expand tavr valv sapien move
pivot trial within next month disappoint pascal approv time
expect later previous contempl
model overal encourag ew initi guidanc believ
compani pois anoth strong year see potenti ew
outperform initi guid behind continu robust tavr growth reiter
overweight rate rais price target base
adj ep estim
top-lin guid expect ew guid sale
underli bracket consensu
underli better guidanc expect
underli ew expect grow faster driven continu bolu
tavr low-risk patient easier prior year compar ew expect roughli
headwind report sale fx next year exhibit
recap ew guidanc busi ew guid tavr transcathet aortic
valv replac sale underli compar
consensu underli guidanc expect
underli outlook better compani initi commentari provid
earn call past octob tailwind tavr growth includ full-
year benefit low-risk approv improv therapi awar ew highlight
new competit modest share compress well modest price
declin two consider contempl tavr guidanc ew set
high bar tavr view ew leadership posit highli defens amidst
compani outlook ssh surgic structur heart
underli bracket street estim underli ahead
guidanc expect underli encourag view
ew expect grow ssh busi despit continu convers transcathet
base procedur growth driver segment includ ew market-lead
inspiri savr valv hand new product launch harpoon continu
next page
competit price pressur product delay advers clinic data litig
ew develop manufactur sell product treat structur heart diseas
provid critic care monitor market leader tavr valv
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
continu previou page
ew initi critic cc guid compar consensu
underli guidanc expect underli growth hemospher
remain key growth driver cc go forward
compani tmtt transcathet mitral transcathet tricuspid guidanc
consensu guidanc expect manag note
tmtt sale would flat best sequenti vs due pascal guid sheath recal
impact case novemb recent pascal hiccup tmtt guidanc
somewhat disappoint remain optimist tmtt opportun front compani
long-term ew sever shot goal
adj ep guid also better expect driven gross margin tax rate ew
initi guidanc modestli better expect
bracket consensu previou estim respect importantli ew
guidanc impli y/i report growth use respect midpoint
guidanc rang better-than-expect ep guidanc driven gross margin tax rate
rel model specif ew expect gross margin vs
expect adj tax rate vs expect ew guid
adj oper margin midpoint in-lin
expect exhibit addit detail
tavr pipelin updat ew lift market expect give sneak peek sapien
regard long-term tavr market opportun ew lift tavr market estim
vs previouslywhich encourag view lt growth driver includ
indic expans therapi awar technolog improv littl
share compani tavr pipelin head investor day ew gave sneak peek
next-gen balloon expand tavr valv call sapien decemb meet ew
alreadi complet first-in-human case plan move pivot trial next
month addit detail provid regard early-tavr ew asymptomat
studi compani note trial enrol enrol expect complet
near-term ew remain confid perform sapien ultra valv
use exclus older prefer command deliveri system
compani expect ultra compris major tavr sale europ
perhap disappoint updat pipelin front dmr degen mitral
regurgit approv pascal expect previous model fda
approv lower tmtt estim primarili
result updat separ ew clasp iif fmr function mitral regurgit studi
continu enrol specif updat given regard ew cardioband mitral repair
devic compani work develop next-gen system improv eas use lower
procedur time ew note sapien transcathet mitral valv replac devic approv
fda begin pivot trial compani expect begin enrol next year
tricuspid side manag said process site select clasp iitr trial
pascal tricuspid set
remain enthusiast long-term prospect front ew mitral
tricuspid market ew pivot trial tmtt on-going next year appear
like opportun take longer initi thought unfold
page
also worth mention uk trial ew alleg patent infring
start week germani trial schedul may juli
stock thought although ew trade meaning premium large-cap med-tech peer
group ew best-in-class financi profil expect double-digit top bottom-lin
growth believ scarciti valu associ level growth ew
enter next year strong momentum think compani initi guidanc
ultim prove conserv reiter overweight rate rais price target
base unchang adj ep estim
page
ew guidanceexpect consensu previou estimateoveral growth rate shown underli basi piper jaffray estim visibl alpha compani reportsew guidanceexpect consensu previou estimatetot op piper jaffray estim visibl alpha compani report exhibit
page
million
sale
revenu report
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
